Albert Labs validates global supply chain for controlled substances

VANCOUVER — Albert Labs International Corp., a fully-integrated biopharmaceutical company bringing prescription medicines to patients, announces the validation of their controlled substance supply chain through the successful global distribution of its psilocybin-based KRN Active Pharmaceutical Ingredient (API).

Albert Labs have successfully distributed their proprietary KRN API from their Health Canada licensed laboratory in Vancouver. This now enables the API to be used as part of their pre-clinical studies at its Infarmed licensed laboratory in Porto, Portugal. This distribution follows a research and development programme allowing for the production and scaling of highly potent yields of its KRN API, for which IP protection has been achieved, using bioreactor technology to ensure the efficient and economical manufacture of its mycelium derived pharmaceutical product.

The company is nearing completion of their KRN-101 pre-clinical studies, which includes full analytical profiling, in-vivo, and in-vitro studies, allowing the medicine to be used in its first, in-human studies in Melbourne, Australia due to begin in Q2 2023.

Dr. Michael Raymont, CEO of Albert Labs: “Validating our supply chain across two of our jurisdictions, North America and Europe, marks a valuable milestone in our operational program. We have demonstrated our ability to distribute KRN-101, a schedule 1 substance, to global, licensed facilities, and this achievement advances our progress by establishing the viability of our supply chain as we prepare for our first-in-human studies.”